Krege S - Search Results

1

[Evaluation of the complementary drug Factor AF2 as a supportive agent in management of advanced urothelial carcinoma. Prospective randomized multicenter study].

Krege S, Hinke A, Otto T, Rübben H. Krege S, et al. Urologe A. 2002 Mar;41(2):164-8. doi: 10.1007/s001200100129. Urologe A. 2002. PMID: 11993095 Clinical Trial. German.

2

[Is risk-oriented therapy in stage I non-seminoma tumor advisable?].

Krege S, Rübben H. Krege S, et al. Urologe A. 1993 May;32(3):171-5. Urologe A. 1993. PMID: 8390119 Review. German.

3

[Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study].

Otto T, Rembrink K, Goepel M, Krege S, Meyer-Schwiekerath M, Rübben H. Otto T, et al. Among authors: krege s. Urologe A. 1996 Mar;35(2):142-5. Urologe A. 1996. PMID: 8650848 Clinical Trial. German.

4

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.

Krege S, Giani G, Meyer R, Otto T, Rübben H. Krege S, et al. J Urol. 1996 Sep;156(3):962-6. doi: 10.1016/s0022-5347(01)65673-8. J Urol. 1996. PMID: 8709374 Clinical Trial.

5

[Are their individual decisions for urinary diversion? Indications and results of 200 consecutive patients].

Krege S, Goepel M, Meyer-Schwickerath M, Otto T, Rübben H. Krege S, et al. Urologe A. 1996 Jul;35(4):291-6. Urologe A. 1996. PMID: 8928357 German.

6

Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical Phase II study.

Otto T, Bex A, Krege S, Walz PH, Rübben H. Otto T, et al. Among authors: krege s. Cancer. 1997 Aug 1;80(3):465-70. doi: 10.1002/(sici)1097-0142(19970801)80:3<465::aid-cncr14>3.0.co;2-v. Cancer. 1997. PMID: 9241080 Clinical Trial.

7

[Therapy with mitomycin C, folic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma--phase II study].

Otto T, Krege S, Otto B, Goepel M, Rübben H. Otto T, et al. Among authors: krege s. Urologe A. 1997 May;36(3):243-7. doi: 10.1007/s001200050098. Urologe A. 1997. PMID: 9265345 Clinical Trial. German.

8

[Long-term outcome of surgical therapy of metastatic non-seminomatous germ cell tumor in advanced tumor stages].

Otto T, Krege S, Goepel M, Baschek R, Rübben H. Otto T, et al. Among authors: krege s. Urologe A. 1997 Jul;36(4):339-42. doi: 10.1007/s001200050108. Urologe A. 1997. PMID: 9340900 German.

9

Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.

Krege S, Rembrink V, Börgermann C, Otto T, Rübben H. Krege S, et al. J Urol. 2001 Jan;165(1):67-71. doi: 10.1097/00005392-200101000-00017. J Urol. 2001. PMID: 11125366 Clinical Trial.

10

[Chronic pain syndrome in uorology].

Krege S, Ludwig M, Kloke M, Rübben H. Krege S, et al. Urologe A. 2003 May;42(5):669-74. doi: 10.1007/s00120-003-0351-2. Epub 2003 Apr 11. Urologe A. 2003. PMID: 12750802 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters